164 results about "Neuroregeneration" patented technology

The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.

The present invention provides compounds of the following structure, wherein R1, R2, R4, R4′, R6, R7, and R15 are defined above: These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.

The present invention provides compounds of the following structure, wherein R1-R9, R15, and n are defined herein. These compounds are useful in treating neurological disorders or complications due to stroke or head injury, and as neuroprotective and neuroregenerative agents.

The present invention provides compounds of the following structure, wherein R1-R9, R15, and n are defined herein.These compounds are useful in treating neurological disorders or complications due to stroke or head injury, and as neuroprotective and neuroregenerative agents.

Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.

The present disclosure provides nerve interface devices, such as passive or active nerve caps or regenerative peripheral nerve interface devices (RPNI), for a subject in need thereof. The nerve interface devices include nerve interface cap devices capable of treating, minimizing, or preventing formation of neuromas in severed or damaged nerve endings. Such a nerve interface device includes a housing that may be formed of a scaffold, such as a biotic material or hydrogel, an autograft, and optionally an electrode and / or conducting polymer. The autograft may be free muscle or free skin tissue, which is attached to the nerve ending to permit reinnervation. The present disclosure also provides methods for treating, minimizing, or preventing neuroma formation in a subject having a severed or damaged nerve, especially a peripheral nerve.

The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and / or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use. Methods for detecting neural regeneration, neural proliferation, neural differentiation, neurite outgrowth and neural survival can be used to develop other neurally active agents.

In accordance with the present invention, there are provided novel compounds that protect neurons and / or promote neuroregeneration and / or promote memory formation. Such compounds are useful for treatment of a variety of neural disorders and conditions. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and / or adjuvants to facilitate delivery thereof across the blood / brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e.g., acute neural injuries, chronic injuries, promoting memory formation, and the like.

An object of the present invention is to provide a nerve regenerating drug, an agent for the promotion of neuropoiesis of a neural stem cell, a neuron obtained by culturing a neural stem cell in the presence of the agent for the promotion of neuropoiesis, and a method of the manufacture of the neuron. In order to achieve the object, the invention provides a nerve regenerating drug comprising a substance that inhibits the activity of glycogen synthase kinase-3, as an active ingredient; an agent for the promotion of neuropoiesis of a neural stem cell comprising the substance as an active ingredient; a neuron obtained by culturing a neural stem cell in the presence of the agent for the promotion of neuropoiesis; and a method of the manufacture of the neuron. The medical drug according to the invention is useful as a therapeutic drug for neurological diseases such as Parkinson's disease, Alzheimer's disease, Down's disease, cerebrovascular disorder, cerebral stroke, spinal cord injury, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, anxiety disorder, schizophrenia, depression and manic depressive psychosis.

The present invention generally relates to improved medical devices, systems, and methods. In many embodiments, devices, systems, and methods for amputating a limb of a patient are provided. In many embodiments, devices, systems, and methods may provide chronic denervation of one or more nerves of a patient as part of a therapeutic treatment. The methods may employ cold for the prevention of neuromas or fibromas associated with amputation of a limb of a patient. Embodiments of the invention include needles that can be advanced through skin or other tissues to cause axonotmesis of a target nerve of the patient and to repeatedly interrupt a regeneration of the nerve so as to provide therapeutic chronic denervation of the target nerve. The therapeutic chronic denervation may delay the formation of neuromas or fibromas in a patient's residual limb and / or may provide long lasting and permanent pain relief associated with the target nerve.

The present invention provides an isolated population of perineurium derived adult stem cells and cells derived thereof. The cells of the invention are obtained from the perineurium of peripheral nerves and demonstrate the ability to expand and differentiate in response to BMP2. The invention also provides methods of using the cells of the invention, for example in methods to promote neuroregeneration and bone formation.

The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity.

Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and / or promote neuroregeneration.

In accordance with the present invention, there are provided novel compounds that have a variety of properties, i.e., antioxidant, anti-inflammatory, antiviral, antibacterial, and antifungal properties. Invention compounds, therefore, have the ability to impart a variety of beneficial physiological effects, e.g., to protect neurons and / or to promote neuroregeneration and / or to promote memory formation and / or to act as protein phosphatase or kinase inhibitors and / or to act as lipoxygenase inhibitors. Such compounds are useful for treatment of a variety of indications, including neurodegenerative diseases and conditions, diabetes, ischemia associated with heart disease, and memory deficit. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and / or adjuvants to facilitate delivery thereof across the blood / brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e.g., acute neural injuries, chronic injuries, promoting memory formation, and the like.

The invention provides a nerve conduit. The nerve conduit is characterized by comprising an inner layer, an outer layer and a cavity; the outer surface of the inner layer is wrapped with the outer layer; the cavity is formed between the inner layer and the outer layer; the inner layer is a hydrophilic cytoskeleton layer manufactured by the electrostatic spinning method; the outer layer is a hydrophobic nerve conduit skeleton layer by the electrostatic spinning method; the cavity is used for storing a bioactive factor solution. The nerve conduit has the characteristics of being proper in strength and hardness, degradable, capable of providing proper neurotrophic active substances, ideal in double-layer or multi-layer structure, semi-permeable, low in cost, short in production cycle, easy to be stored and transported, free of viruses, free of immunological rejection or extremely small in immunological rejection, and wide in applicable scope; the requirement on nerve regeneration process can be met well.

The invention discloses a preparation technology of a novel nerve conduit, and belongs to the technical field of tents of biological tissue engineering. The preparation technology sequentially comprises a preparation technology of GDNF (glial-derived neurotrophic factor)-carried gelatin microspheres, a synthesizing technology of gelatin-methacrylamide hydrogel, a preparation method of polycaprolactone / gelatin electricity texture nerve conduits, and a combining method of the electricity texture nerve conduits and the GDNF-carried gelatin microspheres. The preparation technology has the advantages that a tent structure with good degradability, biological compatibility and biological safety is realized, and the GDNF is controlled and released by the GDNF-carried gelatin microspheres; compared with blank groups and collagen conduit groups, the regeneration of peripheral nerves is effectively promoted, and the structure and function of restoring damaged nerves can reach the effect similar to the effect of autotransplantation groups; the defect nerves can be bridged, and the stability of axon regeneration environment can be maintained; the invasion of peripheral connective tissues is prevented; the saturing of near and far-heart breaking ends of smaller nerve defect is solved, and the restoration of larger nerve defect is solved.

The invention belongs to the field of biological medicine, and particularly relates to a Nogo-A receptor binding peptide as well as a derivative and an application thereof. The amino acid residue sequence of the Nogo-A receptor binding peptide is HIYTALV or GFATITG. The derivative of the binding peptide is a product obtained through conventional modification of an amino terminal or a carboxyl terminal of a Nogo-A receptor binding peptide fragment on a Nogo-A receptor binding peptide amino acid side chain group or a product obtained by connecting a label used for peptide or protein detection or purification on the Nogo-A receptor binding peptide. The binding peptide and the derivative of the binding peptide can be bound with NgR in vitro, nerve regeneration is promoted by preventing binding of NgR and Nogo-A, nerve regeneration barriers caused by central nervous injury diseases can be treated, recovery of a central nervous function is promoted, and the binding peptide and the derivative can be widely applied in the medical and biological fields.

The present invention discloses achyranthes bidentata polypeptide, a production method and applications, and the achyranthes bidentata polypeptide is produced with the steps including polypeptide extraction, polypeptide separation, etc. The achyranthes bidentata polypeptide is used to the preparation of drugs and health products for treating peripheral nerve injuries, cerebrovascular accidents, ischemic brain injuries, cerebral traumas, optic nerve injuries, spinal cord injuries and central nervous system injuries, antiaging and preventing neurodegenerative diseases. Experiments prove that the extracted achyranthes bidentata polypeptide (protein) of the present invention has the effects of promoting the growth of nerves, preventing the fading of nerve cells and promoting the regeneration of injured nerves, the source of medicinal materials is single, the preparation method is advanced, the technique is reasonable, the ingredients of preparations are definite, safety is high, and pharmacological action is obvious.

In accordance with the present invention, there are provided novel compounds that protect neurons and / or promote neuroregeneration and / or promote memory formation. Such compounds are useful for treatment of a variety of neural disorders and conditions. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and / or adjuvants to facilitate delivery thereof across the blood / brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e.g., acute neural injuries, chronic injuries, promoting memory formation, and the like.

To supply substantially isolated neural cells in a large amount, and to provide an application means for a neurodegenerative medicine or the like for a neurodegenerative disease, a nervous damage or the like. A method for producing a substantially isolated neural cell, comprising the step of carrying out the suspension culture of embryonic stem cells in the presence of an astrocyte conditioned medium or ingredients substantially equivalent to the conditioned medium; and a neural cell obtained thereby; a cell pharmaceutical composition comprising, as an active ingredient, the isolated neural stem cell; and a method for treating a neurodegenerative disease or nervous damage, comprising the step of introducing the neural cell into a neurodegenerative site or a nervous damage site.

Compositions and methods to promote nerve regeneration or to confer neuroprotection and prevent or inhibit neuronal degeneration within the nervous system, either the central nervous system or the peripheral nervous system, are provided. Treatment involves administering NS-specific activated T cells, or an NS-specific antigen or analog thereof, a peptide derived therefrom or an analog or derivative of said peptide, or a nucleotide sequence encoding such an antigen or peptide, or any combination thereof.

The present invention discloses compositions and methods for the treatment of injury or disease of the nervous system CNS. In a particular embodiment, the invention provides methods of treatment using non-recombinant activated antiself T-cells that recognize an antigen of the NS or a peptide derived therefrom or a derivative thereof to promote nerve regeneration or to prevent or inhibit axonal degeneration within the NS. The invention also provides methods of treatment using a NS-specific antigen or peptide derived therefrom or a derivative thereof or a nucleotide sequence encoding said antigen or peptide to promote nerve regeneration or to prevent or inhibit axonal degeneration in NS, i.e., the CNS and / or PNS. The NS-specific antiself activated T-cells may be administered alone or in combination with NS-specific antigen or peptide derived therefrom or a derivative thereof or a nucleotide sequence encoding said antigen or peptide or any combination thereof.

The present invention is directed to a device and method for a nanofiber wrap to minimize inflation and scarring of nerve tissue and maximize the nutrient transport. More particularly, the present invention is directed to a novel semi-permeable nanofiber construct prepared from biocompatible materials. The nanofiber construct is applied around a nerve repair site following end-to-end anastomosis. The nanofiber construct is porous and composed of randomly oriented nanofibers prepare using an electrospinning method. The nanofiber construct has a wall that is approximately 50-100 μm thick with pores smaller than 25 μm. The nanofiber construct prevents inflammatory cells from migrating into the nerve coaption site, while still permitting the diffusion of growth factors and essential nutrients. The nanofiber construct allows for enhanced neuroregeneration and optimal function outcomes.

The invention discloses a nerve regeneration gel as well as a preparation method and application thereof. The matrix of the nerve regeneration gel is formed by fibrinogen, thrombin, laminin and fibronectin; the nerve regeneration gel contains procyanidine, sonic hedgehog, an epidermal growth factor, neurenergen-3 and a vascular endothelial growth factor. In-vitro test and animal test show that thegel is capable of accelerating neuron regeneration and neurite extension and repairing the injured nerve tissue. The matrix of the gel comprises fibrin, laminin and fibronectin and is capable of reducing formation of cavities and accelerating adhesion and proliferation of endogenous neural stem cells; the procyanidine in the gel is capable of resisting oxidation and inhibiting inflammation; the sonic hedgehog, the epidermal growth factor and the neurenergen-3 are capable of accelerating proliferation of the stem cells and differentiation to neurons of the stem cells; the vascular endothelialgrowth factor is capable of accelerating generation of blood vessels. The gel can be formed in situ on injured parts and can be used for treating nervous system injury.

Pharmaceutical compositions and methods for preventing or inhibiting neuronal degeneration, or for promoting nerve regeneration, in the central nervous system (CNS) or peripheral nervous system (PNS), in the treatment of an injury, disorder or disease of the CNS or PNS, comprise antigen-presenting cells, preferably dendritic cells, that have been pulsed with an agent selected from the group consisting of: (a) a nervous system (NS)-specific antigen or an analog thereof; (b) a peptide derived from an NS-specific antigen or from an analog thereof, or an analog or derivative of said peptide; (c) a copolymer selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide or polypeptide, and poly-Glu<50> Tyr<50>; and (d) a non-self antigen.

The invention provides application of acellular nerve hydrogel to preparation of a peripheral nerve injury repairing composition. The peripheral nerve injury repairing composition is prepared by using the acellular nerve hydrogel, so the peripheral nerve regeneration microenvironment can be simulated well, extension and myelination of axon can be promoted, the PSD95 expression level of nerve cells is reduced, and occurrence of pathological neuralgia and neuroma is inhibited. An electrophysiological experiment proves that although the acellular nerve hydrogel inhibits formation of cynapse between the nerve cells, the acellular nerve hydrogel does not influence generation of action potential and conduction along axion and can repair peripheral nerve injury well.

Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.

The invention relates to a construction method of an artificial neural network sample catheter for repairing spinal cord injury, in particular to a method for constructing a functional artificial neural network sample catheter by using a porous gelatin sponge cylindrical stand and application thereof. When applied, the functional artificial neural network sample catheter is transplanted to an injured part of complete transverse or semi-transverse spinal cord so as to better promote the injured central nervous regeneration and functional repair. The method has significance for enhancing protection of injured neurons after spinal cord injury, promoting reconstruction of a neural network, improving the quality of life of the wounded and sick, lightening the social and family burden and promoting the social and economic development of China at a biological tissue engineering level.

The invention discloses an acellular xenograft and a preparation method thereof. The method includes the following steps: immersing peripheral nerves of the isolated mammal with alkaline solution, surfactant solution, degreasing agent and PBS buffer solution in order, freeze-drying and sterilizing to obtain the acellular xenograft. The acellular xenograft prepared by the invention has good histocompatibility, can regenerate nerve regeneration pathways, guide axon regeneration, accelerate nerve functional repair, and has good clinical application prospect in the field of repair of the peripheral nerves.